A Gout Flare Caused by the Administration of Platelet Rich Plasma: A Clinical Case
Journal Title: Journal of Regenerative Medicine & Biology Research - Year 2023, Vol 4, Issue 1
Abstract
The therapy with Platelet Rich Plasma (PRP) administered in degenerated or injured musculoskeletal tissues is a new and promising regenerative treatment option. Traditionally, it is considered that as PRP represents an autologous (to the patient) blood product, the potential for serious side effects is neglectable. Consequently, it is important that any significant negative consequences are well described. We present a fifty-five years old male patient, complaining of pain and stiffness in his right ankle joint due to multiple traumas during his earlier sport career. He had no any contraindications and PRP was injected intraarticularly under ultrasound guidance. On the next day, the patient developed an intensive pain and swelling in the regions of the right ankle and the dorsum of the right foot. The acute phase reactants were elevated and there was no leukocytosis. On ultrasound examination, there was an effusion in the tibiotalar and talonavicular joints. Arthrocentesis was performed and the microscopic examination revealed the typical needle shaped monosodium urate crystals inside the joint fluid and no bacteria. Consequently, the diagnosis of acute gouty flare was made (the patient has a history of gout, but did not have any flares in the past two years). As PRP concentrate contains naturally many proinflammatory molecules, we speculate that some of them may activate the macrophages that residue normally in the synovium and the capsule of the injected joint. The activated macrophages further may react to the MSU crystals deposited there, leading to the development of a gouty flare. In conclusion, the possibility of a flare should be explained to gouty patients, candidate for PRP treatment.
Authors and Affiliations
Plamen Todorov, Anastas Batalov
Keywords
Related Articles
- EP ID EP713571
- DOI https://doi.org/10.46889/JRMBR.2023.4103
- Views 30
- Downloads 0
Use of Stem Cells to Treat Left Ventricular Hypertrophy
Left Ventricular Hypertrophy is a multifactorial condition involving genetic and signaling pathways. Current recommendations for treating hypertensive LVH include ACE inhibitors, RAS and CCBs. Despite numerous drug thera...
Advancing Extracellular Vesicle Therapeutics into Clinical Trials for Central Nervous System Disorders
In December 2023, the US Food and Drug Administration released a draft guidance document titled “Potency Assurance for Cellular and Gene Therapy Products Draft Guidance for Industry” for public comment [1]. Potency assay...
The Application of Transgenesis to Abraham Trembley’s Hydra, an Ancient Animal Model for the Study of Regeneration that has now entered the 21st Century
Developmental biology and regenerative biology began with the studies of Abraham Trembley who was a mathematician. Trembley initiated studies with the freshwater hydrozoan, hydra to determine if the organism was a plan...
Criteria to Distinguish Endogenous Telomerase-Positive Totipotent Stem Cells from Exosomes as Major Players in Regenerative Medicine
Endogenous adult-derived Totipotent Stem Cells (TSCs) and tissue-resident exosomes are major players in the field of regenerative medicine. TSCs provide the undifferentiated building blocks for tissue repair, while exo...
Comparison of Resuspension Techniques on the Cellular and Cytokine Characteristics of Platelet Rich Plasma: A Pilot Study
Background: Platelet Rich Plasma (PRP) is increasingly used for a variety of musculoskeletal ailments such as tendinopathy and arthritis. There are numerous protocols for preparing PRP, but to our knowledge there have be...